DDInter336 DDInter1259
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Celecoxib {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Nalidixic acid
Celecoxib {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Celecoxib {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Nalidixic acid
Celecoxib {u} (Compound) upregulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) is regulated by {v} (Gene) DCUN1D4
DCUN1D4 {u} (Gene) is upregulated by {v} (Compound) Nalidixic acid
Celecoxib {u} (Compound) binds {v} (Gene) PDPK1
PDPK1 {u} (Gene) interacts with {v} (Gene) PAK1
PAK1 {u} (Gene) is upregulated by {v} (Compound) Nalidixic acid
Celecoxib {u} (Compound) upregulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) is regulated by {v} (Gene) SLC5A6
SLC5A6 {u} (Gene) is downregulated by {v} (Compound) Nalidixic acid
Celecoxib {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is associated with {v} (Gene) PAK1
PAK1 {u} (Gene) is upregulated by {v} (Compound) Nalidixic acid
Celecoxib {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) regulates {v} (Gene) PAK1
PAK1 {u} (Gene) is upregulated by {v} (Compound) Nalidixic acid
Celecoxib {u} (Compound) palliates {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) downregulates {v} (Gene) MAP7
MAP7 {u} (Gene) is downregulated by {v} (Compound) Nalidixic acid
Celecoxib (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Nalidixic acid (Compound)
Celecoxib (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Norfloxacin (Compound) and Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Norfloxacin (Compound) and Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Celecoxib (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Lomefloxacin (Compound) and Lomefloxacin (Compound) resembles Nalidixic acid (Compound)
Celecoxib (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is regulated by DCUN1D4 (Gene) and DCUN1D4 (Gene) is upregulated by Nalidixic acid (Compound)
Celecoxib (Compound) binds PDPK1 (Gene) and PDPK1 (Gene) interacts with PAK1 (Gene) and PAK1 (Gene) is upregulated by Nalidixic acid (Compound)
Celecoxib (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is regulated by SLC5A6 (Gene) and SLC5A6 (Gene) is downregulated by Nalidixic acid (Compound)
Celecoxib (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is associated with PAK1 (Gene) and PAK1 (Gene) is upregulated by Nalidixic acid (Compound)
Celecoxib (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) regulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Nalidixic acid (Compound)
Celecoxib (Compound) palliates hematologic cancer (Disease) and hematologic cancer (Disease) downregulates MAP7 (Gene) and MAP7 (Gene) is downregulated by Nalidixic acid (Compound)